GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genenta Science SPA (NAS:GNTA) » Definitions » Insider Ownership

Genenta Science SPA (Genenta Science SPA) Insider Ownership : 0.00 % (As of May. 25, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Genenta Science SPA Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Genenta Science SPA's insider ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Genenta Science SPA's Institutional Ownership is 4.05%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Genenta Science SPA's Float Percentage Of Total Shares Outstanding is 61.23%.


Genenta Science SPA Insider Ownership Historical Data

The historical data trend for Genenta Science SPA's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genenta Science SPA Insider Ownership Chart

Genenta Science SPA Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Insider Ownership
- - - - -

Genenta Science SPA Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Insider Ownership Get a 7-Day Free Trial Premium Member Only - - - - -

Genenta Science SPA Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.


Genenta Science SPA (Genenta Science SPA) Business Description

Traded in Other Exchanges
Address
Via Olgettina No. 58, Milan, ITA, 20132
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's lead product includes Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain, and TEMs -Immuno-Gene Therapy.